Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Antibiotics (Basel, Switzerland)
2025
|
| Online Access: | https://pubmed.ncbi.nlm.nih.gov/41463755/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Plasma and Muscle Pharmacokinetics of Ceftriaxone in Nile Tilapia () After Different Administration Routes. Marín, Pedro Corum, Orhan Corum, Duygu Durna Badillo, Elena Yuste, María Teresa Yildirim, Onder Terzi, Ertugrul Gonzales, Ruby C Arriesgado, Dan M Navarro, Victor R Uney, Kamil : The aim of this study was to determine the plasma and muscle pharmacokinetics of ceftriaxone (25 mg/kg) in tilapia after different administration routes. : Two hundred and sixteen fish maintained at 30 ± 1.5 °C were divided equally into three treatment groups: intravascular (IV), intraperitoneal (IP), and intramuscular (IM). Ceftriaxone concentrations were quantified using high-performance liquid chromatography, and pharmacokinetic parameters were calculated by non-compartmental analysis. : The plasma total body clearance, volume of distribution at steady state, and elimination half-life (t) were 0.22 L/h/kg, 0.85 L/kg, and 5.27 h, respectively. The t values were comparable among the IV, IP, and IM injection groups. The peak plasma concentration was 37.71 ± 3.12 µg/mL and 40.51 ± 2.77 µg/mL following IP and IM injection, respectively. The bioavailability was 67.04% for IP and 101.48% for IM. The peak muscle concentration was 9.49 ± 0.75 µg/g for IV, 5.71 ± 0.85 µg/g for IP, and 12.24 ± 2.41 µg/g for IM injection. The AUC/AUC ratio was 0.23, 0.18, and 0.30 for the IV, IP, and IM groups, respectively. The AUC/AUC indicates the ratio of drug penetration into the muscle, and a value less than 1 indicates that ceftriaxone penetrates into muscle tissue at a low ratio. : These results indicate that ceftriaxone is well absorbed after IP and IM injections and passes into muscle tissue at a low tissue penetration. Ceftriaxone can be administered via IP and IM injection in Nile tilapia; nevertheless, its therapeutic efficacy requires evaluation.